Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Topical anti-infective formulations

An anti-infection, topical technology, applied in biocides, antibacterials, animal repellents, etc.

Inactive Publication Date: 2006-03-08
БИОСИНЕКСУС ИНКОРПОРЕЙТЕД
View PDF11 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] Decolonization of the skin to prevent infection and to treat existing conditions of skin and wound infection remains particularly challenging due to the delicate balance between skin flora

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Topical anti-infective formulations
  • Topical anti-infective formulations
  • Topical anti-infective formulations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Example 1 - In Vivo Efficacy of Lysostaphin Topical Cream

[0094] Lysostaphin was formulated as a topical cream to examine its efficacy against Staphylococcus aureus in a mouse skin infection model ( figure 2 ). Application of six doses of 0.5% w / w lysostaphin cream over two days eradicated the infection in three out of four mice, leaving only few colonies in the remaining mice. 0.25% w / w lysostaphin cream also showed considerable activity, clearing the infection in one of three mice and reducing the infectious titer in two of them by more than 3 logs, but it was more effective than 0.5% w / w lysostaphin cream was more than ten-fold lower, indicating an exponential dose response for this therapy. Surprisingly, the placebo cream also had considerable staphylococcal killing activity, reducing bacterial titers in the skin by approximately 100-fold. The activity of the lysostaphin cream was apparently a combined or synergistic killing effect of both lysostaphin and th...

Embodiment 2

[0096] Example 2 - In Vivo Efficacy of Nisin Topical Cream

[0097] Nisin was formulated as a topical cream to test its efficacy against Staphylococcus aureus and Pseudomonas aeruginosa in a mouse skin infection model ( Figure 4 and 5 ), which helps prevent the emergence of lysostaphin-resistant organisms. In combination with EDTA, the bactericidal activity of nisin extends to Gram-negative bacteria, which are also important causes of infectious skin diseases. Although nisin cream is not as effective as lysostaphin cream ( figure 2 and 4 ), but nisin still had considerable activity against S. aureus after two days of treatment. Nisin cream at 0.5% w / w did not eradicate infection in any of the animals, but did reduce bacterial titers by approximately 3.5 logs. More importantly, when small doses (0.1% w / w each) of lysostaphin and nisin were combined in a single cream formulation, skin infections were completely eradicated in all animals tested. Neither 0.1% w / w lysosta...

Embodiment 3

[0099] Example 3 - In vivo efficacy of topical creams without anti-infective agents

[0100] The in vivo efficacy of the cream formulation was demonstrated in a skin graft model. S. aureus was colonized into the skin of hairless mice by swabbing the bacteria on the skin surface (no wound or suture). The grafted skin was treated with the topical cream base prepared in Example 1 or the topical cream prepared in Example 1 plus 1% w / w DMSO for two days, three times a day. Lysostaphin in a topical cream only reduced skin colonization by about half, while the addition of the absorption enhancer DMSO to a cream containing no lysostaphin or any other anti-infective agent resulted in virtually clear completely ( Figure 6 ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Topical compositions containing an effective amount of lysostaphin and / or one or more lantibiotics in a pharmaceutically acceptable carrier for topical application. Methods for treating skin or wound infections, including, but not limited to infected abrasions, skin or surface cuts, burns or surgical incisions or decubiti, with the topical compositions are also disclosed.

Description

Background technique [0001] Bacterial skin and wound infections are a significant problem, especially in public settings such as hospitals, nursing homes, schools (especially athlete locker rooms), and infirmaries. High-risk individuals include infants, the elderly, those undergoing aggressive treatment in the hospital or outpatient setting (essentially any patient before leaving the hospital), those with a variety of conditions that predispose to skin infections (including the presence of foreign objects, weakened immunity, immunosuppressed ), convalescent patients and chronic patients requiring frequent hospitalization. In nonhuman patients, individuals at risk include zoo animals, herds, and animals kept in close proximity (e.g., animals kept in veterinary facilities and stables), including but not limited to pigs, cattle, sheep, goats, etc. . [0002] These individuals are at high risk of infection in the skin or wounds spreading into or otherwise damaging other organ sy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/74A61K38/00A01N37/18A61K38/16A61K38/48A61K45/06
CPCC12Y304/00A61K47/14A61K38/4886A61K47/44C12Y304/24075A61K38/164A61K31/74A61K47/26A61K9/0014A61K9/00A61K9/06A61K47/32A61K45/06A61P17/02A61P31/04A61P43/00A61K2300/00
Inventor S·M·威尔士A·沙J·J·蒙德
Owner БИОСИНЕКСУС ИНКОРПОРЕЙТЕД
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com